---
title: "Ginkgo Bioworks Q2 FY26 GAAP net loss widens to $57 million; revenue drops 48% to $20 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295012967.md"
description: "Ginkgo Bioworks reported Q2 FY26 GAAP net loss widening to $57 million, with revenue dropping 48% to $20 million due to program rationalization. Adjusted EBITDA loss increased to $36 million. The company holds $302 million in cash and reaffirmed its full-year cash burn outlook of $125-150 million. Additionally, Ginkgo secured government-backed autonomous lab work at several universities and initiated a $47 million build at PNNL’s EMSL."
datetime: "2026-08-05T20:46:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295012967.md)
  - [en](https://longbridge.com/en/news/295012967.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295012967.md)
generator: "portal-rs"
---

# Ginkgo Bioworks Q2 FY26 GAAP net loss widens to $57 million; revenue drops 48% to $20 million

-   Ginkgo Bioworks posted Q2 2026 revenue of USD 20 million, down 48% on ongoing program rationalization tied to restructuring. \* GAAP net loss from continuing operations widened to USD 57 million. \* Adjusted EBITDA loss widened to USD 36 million. \* Cash, cash equivalents and marketable securities totaled USD 302 million at June 30, 2026; full-year cash burn outlook reaffirmed at USD 150-125 million. \* Won government-backed autonomous lab work at MIT, Caltech, Northwestern and the University of Maryland; began a USD 47 million build at PNNL’s EMSL. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-053319), on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [DNABW.US](https://longbridge.com/en/quote/DNABW.US.md)
- [DNA.US](https://longbridge.com/en/quote/DNA.US.md)

## Related News & Research

- [Ginkgo Bioworks joins Waterfall Scientific-led ARPA-H consortium to build autonomous RNA drug manufacturing system](https://longbridge.com/en/news/298590935.md)
- [DNA: Q2 2026 revenue dropped 48% year-over-year, with major autonomous lab contracts secured](https://longbridge.com/en/news/295007946.md)
- [S&P Global announces Q3 2026 dividend of R$ 0.09 per unit, payable Sept. 16](https://longbridge.com/en/news/298766498.md)
- [Benfica Futebol SAD corrects AGM date to Oct. 1, 2026 from Sept. 30, 2026](https://longbridge.com/en/news/298497181.md)
- [Evropi Holdings moves H1 2026 results publication to Sept. 17 from Sept. 23](https://longbridge.com/en/news/298610315.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**